Detail akcie Anteris Tech Rg online

Business Summary: Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Anteris Technologies Global Corp revenues increased from $769K to $1.6M. Net loss increased from $21.9M to $64.9M. Revenues reflect United States segment increase from $444K to $1.3M, Australia segment increase from $6K to $25K. Higher net loss reflects Research and development expense - Balan increase from $14M to $47.2M (expense), Selling.